Annual EBIT
-$148.66 M
-$37.37 M-33.57%
December 31, 2023
Summary
- As of February 7, 2025, AKRO annual earnings before interest & taxes is -$148.66 million, with the most recent change of -$37.37 million (-33.57%) on December 31, 2023.
- During the last 3 years, AKRO annual EBIT has fallen by -$68.51 million (-85.47%).
- AKRO annual EBIT is now -978.97% below its all-time high of -$13.78 million, reached on December 31, 2018.
Performance
AKRO EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$71.46 M
-$16.70 M-30.50%
September 30, 2024
Summary
- As of February 7, 2025, AKRO quarterly earnings before interest & taxes is -$71.46 million, with the most recent change of -$16.70 million (-30.50%) on September 30, 2024.
- Over the past year, AKRO quarterly EBIT has dropped by -$32.69 million (-84.31%).
- AKRO quarterly EBIT is now -16873.63% below its all-time high of -$421.00 thousand, reached on March 31, 2018.
Performance
AKRO Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$232.86 M
-$32.69 M-16.33%
September 30, 2024
Summary
- As of February 7, 2025, AKRO TTM earnings before interest & taxes is -$232.86 million, with the most recent change of -$32.69 million (-16.33%) on September 30, 2024.
- Over the past year, AKRO TTM EBIT has dropped by -$115.79 million (-98.91%).
- AKRO TTM EBIT is now -55210.45% below its all-time high of -$421.00 thousand, reached on March 31, 2018.
Performance
AKRO TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
AKRO EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.6% | -84.3% | -98.9% |
| 3 y3 years | -85.5% | -193.7% | -137.2% |
| 5 y5 years | -979.0% | -338.2% | -410.1% |
AKRO EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -47.5% | at low | -214.8% | at low | -131.0% | at low |
| 5 y | 5-year | -225.6% | at low | -477.3% | at low | -410.1% | at low |
| alltime | all time | -979.0% | at low | <-9999.0% | at low | <-9999.0% | at low |
Akero Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$71.46 M(+30.5%) | -$232.86 M(+16.3%) |
| Jun 2024 | - | -$54.76 M(+4.6%) | -$200.17 M(+14.0%) |
| Mar 2024 | - | -$52.35 M(-3.6%) | -$175.64 M(+18.1%) |
| Dec 2023 | -$148.66 M(+33.6%) | -$54.29 M(+40.0%) | -$148.66 M(+27.0%) |
| Sep 2023 | - | -$38.77 M(+28.3%) | -$117.07 M(+3.1%) |
| Jun 2023 | - | -$30.23 M(+19.1%) | -$113.52 M(+2.6%) |
| Mar 2023 | - | -$25.37 M(+11.8%) | -$110.64 M(-0.6%) |
| Dec 2022 | -$111.29 M(+10.4%) | -$22.70 M(-35.6%) | -$111.29 M(-8.0%) |
| Sep 2022 | - | -$35.22 M(+28.8%) | -$121.02 M(+9.9%) |
| Jun 2022 | - | -$27.35 M(+5.1%) | -$110.13 M(-1.4%) |
| Mar 2022 | - | -$26.03 M(-19.7%) | -$111.72 M(+10.8%) |
| Dec 2021 | -$100.78 M | -$32.42 M(+33.3%) | -$100.81 M(+2.7%) |
| Sep 2021 | - | -$24.33 M(-15.9%) | -$98.17 M(+2.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$28.93 M(+91.3%) | -$95.38 M(+15.1%) |
| Mar 2021 | - | -$15.13 M(-49.2%) | -$82.90 M(+3.4%) |
| Dec 2020 | -$80.15 M(+75.6%) | -$29.78 M(+38.3%) | -$80.15 M(+20.4%) |
| Sep 2020 | - | -$21.54 M(+30.9%) | -$66.59 M(+8.5%) |
| Jun 2020 | - | -$16.45 M(+32.9%) | -$61.36 M(+16.8%) |
| Mar 2020 | - | -$12.38 M(-23.7%) | -$52.52 M(+15.0%) |
| Dec 2019 | -$45.65 M(+231.3%) | -$16.22 M(-0.5%) | -$45.65 M(+40.9%) |
| Sep 2019 | - | -$16.31 M(+114.3%) | -$32.40 M(+81.8%) |
| Jun 2019 | - | -$7.61 M(+38.0%) | -$17.82 M(-5.6%) |
| Mar 2019 | - | -$5.51 M(+85.7%) | -$18.87 M(+37.0%) |
| Dec 2018 | -$13.78 M | -$2.97 M(+71.9%) | -$13.78 M(+27.5%) |
| Sep 2018 | - | -$1.73 M(-80.1%) | -$10.81 M(+19.0%) |
| Jun 2018 | - | -$8.66 M(+1957.5%) | -$9.08 M(+2057.5%) |
| Mar 2018 | - | -$421.00 K | -$421.00 K |
FAQ
- What is Akero Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Akero Therapeutics?
- What is Akero Therapeutics annual EBIT year-on-year change?
- What is Akero Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Akero Therapeutics?
- What is Akero Therapeutics quarterly EBIT year-on-year change?
- What is Akero Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Akero Therapeutics?
- What is Akero Therapeutics TTM EBIT year-on-year change?
What is Akero Therapeutics annual earnings before interest & taxes?
The current annual EBIT of AKRO is -$148.66 M
What is the all time high annual EBIT for Akero Therapeutics?
Akero Therapeutics all-time high annual earnings before interest & taxes is -$13.78 M
What is Akero Therapeutics annual EBIT year-on-year change?
Over the past year, AKRO annual earnings before interest & taxes has changed by -$37.37 M (-33.57%)
What is Akero Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of AKRO is -$71.46 M
What is the all time high quarterly EBIT for Akero Therapeutics?
Akero Therapeutics all-time high quarterly earnings before interest & taxes is -$421.00 K
What is Akero Therapeutics quarterly EBIT year-on-year change?
Over the past year, AKRO quarterly earnings before interest & taxes has changed by -$32.69 M (-84.31%)
What is Akero Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of AKRO is -$232.86 M
What is the all time high TTM EBIT for Akero Therapeutics?
Akero Therapeutics all-time high TTM earnings before interest & taxes is -$421.00 K
What is Akero Therapeutics TTM EBIT year-on-year change?
Over the past year, AKRO TTM earnings before interest & taxes has changed by -$115.79 M (-98.91%)